First Report on Infant Acute Urticaria after Mother’s Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report
Abstract
Pentavalent antimonials are still the first drug of choice for the treatment of cutaneous leishmaniasis (CL). Like other treatments, they can cause adverse reactions including musculoskeletal pain, gastrointestinal disturbances, and mild to moderate headaches. In this paper, we report the first case of an infant who developed acute urticaria after her mother’s parenteral use of meglumine antimoniate (glucantime).
Mahmoudvand H, Sharifi I, Fasihi Harandi M, Shokohi M, Shakibaie M, Rezaei Rabani T, Jahanbakhsh S, Ghasemi AA (2014). Anti-leishmania effects of methotrexate (MTX) alone and in combination with meglumine antimoniate (MA) against Iranian isolate of sensitive and MA-resistant Leishmania tropica: An invitro assay. Asian Pacific J Trop Med, 4: 412-420.
Mohebali M, Fotouhi A, Hooshmand B, Zarei Z, Akhoundi B, Rahnema A, et al. (2007). Comparison of miltefosine and meglumine antimoniate (GlucantimeR) for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Trop, 103(1): 33-40.
Oliveira LF, Schubach AO, Martins MM, Passos SL, Oliveira RV, Marzochi MC, et al. (2011). Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop, 118(2): 87-96.
Roberts WL, McMurray WJ, Rainey PM (1998). Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime). Antimicrob Agents Chemother, 42(5): 1076-1082.
U.S. National Library of Medicine,National Institutes of Health, Health & Human Services: http://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm.
| Files | ||
| Issue | Vol 45 No 9 (2016) | |
| Section | Case Report(s) | |
| Keywords | ||
| Cutaneous leishmaniasis Meglumine antimoniate (Glucantime) Adverse reactions | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
